Therma Bright Secures Purchase Order For 1,750 Venowave W5 Units From National Distributor - DME Authority of Nashville, TN
MWN-AI** Summary
Therma Bright Inc. (TSXV: THRM) has recently secured a significant purchase order for 1,750 units of its Venowave VW5 device from DME Authority, a national distributor based in Nashville, Tennessee. This partnership marks a critical step in expanding the distribution of Therma Bright's vascular compression therapy solutions and comes on the heels of successful pilot trials conducted by DME and its partner network. The order aligns with a previously signed Letter of Intent, positioning DME as a "Premier Distributor Partner" for Therma Bright.
The total reimbursement for the initial order amounts to approximately $1,434,212 USD, or $2,051,602 CAD, demonstrating the financial promise of this collaboration. Rob Fia, CEO of Therma Bright, expressed enthusiasm regarding the traction of the company’s inventory and the impending production adjustments to meet this rising demand. He indicated that new manufacturing initiatives are already underway to sufficiently stock the growing distribution network.
The Venowave VW5 is an innovative, battery-operated device designed for post-operative care, significantly improving blood circulation and reducing pain and swelling. It is the only Medicare-approved mobile mechanical compression system available in the U.S. under its specific HCPCS code, emphasizing its market viability. The global compression therapy market is projected to grow substantially, from $4.18 billion in 2024 to $6.72 billion by 2033, with a CAGR of 7.30% from 2025 to 2033, indicating a strong market potential for Therma Bright's products.
With a robust national distribution program now taking shape, Therma Bright aims to enhance patient care and capitalize on the growing healthcare technology sector, positioning itself for ongoing success in the medical device industry.
MWN-AI** Analysis
Therma Bright Inc. (TSXV: THRM) has recently announced a significant purchase order with DME Authority for 1,750 units of their Venowave VW5, positioning the company favorably within the expanding vascular compression therapy market. This order not only reflects strong demand for their product but also stands to generate approximately $1.43 million USD in reimbursements under the HCPCS code E0683—indicating a solid revenue stream that enhances investor confidence.
The global compression therapy market is projected to grow from $4.18 billion in 2024 to $6.72 billion by 2033, representing a CAGR of 7.30%. Given this market trajectory, Therma Bright is aligning itself with a robust growth sector. Notably, the Venowave VW5 is the only Medicare-approved mobile mechanical compression system in the U.S., which uniquely positions it within the competitive landscape.
Investors should pay close attention to the company’s capacity to scale production in response to this demand. CEO Rob Fia's remarks about ramping up manufacturing indicate an understanding of market dynamics and proactive measures to meet consumer needs. The successful pilot trials conducted by DME Authority further validate the product’s efficacy in enhancing blood circulation and managing post-operative recovery, which could lead to increased adoption across healthcare facilities.
As the company navigates its production ramp-up, potential investors should consider the risk factors mentioned in the forward-looking statements, including uncertainties around future sales performance. However, the favorable partnership with DME Authority, combined with the promising market outlook, suggests that Therma Bright presents a worthwhile opportunity for investors seeking exposure to innovative medical technologies.
In conclusion, given the current data and market sentiment, Therma Bright appears well-positioned for growth. Monitoring production capabilities, sales performance, and broader market trends will be crucial for assessing further investment potential.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
National Distributor Eager To Begin Sales & Marketing Of Vascular Compression Therapy Solutions
Toronto, Ontario--(Newsfile Corp. - January 21, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce that it has secured a purchase order for 1,750 Venowave VW5 from national distribution partner DME Authority of Nashville, Tennessee. DME, along with their partner network, was just one of the Company's national distributors who have experienced successful pilot trials.
Last month, distribution partner DME Authority signed a Letter of Intent (LOI) for distributing the Venowave VW5 to its U.S. distribution network. This purchase order brings both companies one step closer to the outlined LOI that positions DME as a 'Premier Distributor Partner' for Therma Bright. This initial purchase order for 1750 Venowave VW5 units offers HCPCS code reimbursements that total $1,434,212 USD, which equates to $2,051,602 CAD.
"It is very exciting to see our distribution program with DME come to fruition," shared Rob Fia, CEO of Therma Bright. "Our current inventory is seeing great traction, so we've begun the process with our new manufacturing partner to begin production on new inventory, which we anticipate will arrive to meet the demand of our growing national distribution network. As always, we will keep the market updated on our progress with sales and manufacturing."
The global compression therapy market was valued at $4.18 billion in 2024 and is projected to grow to $6.72 billion by 2033. This represents a compound annual growth rate (CAGR) of 7.30% from 2025 to 2033," per a Straits Research press announcement in November 2024.
About Venowave VW5
The Venowave VW5 is a compact, battery-operated peristaltic pump designed to diminish post-op pain & swelling and enhance blood circulation while harnessing the multitude of advantages that come with increased venous blood flow by 64% after 2 minutes of use, and 88% increased blood flow after 50 minutes of use. When positioned below the knee, the device generates a wave-form motion that promotes fluid displacement, improving circulation and lymphatic function. The FDA-designated Durable Medical Equipment (DME) device is currently the only Medicare approved reimbursable mobile mechanical compression system available in the US under its HCPCS code E0683, which provides a simple and comfortable mobile treatment solution for patients needing to accelerate post-operative recovery periods while also managing longer term pain and swelling issues.
About DME Authority, LLC
DME Authority partners with a select network of top-tier medical distributors and healthcare providers to deliver outcome-driven solutions that set new standards for patient care. By aligning with forward-thinking organizations, we bring innovative sales and distribution strategies to life, backed by comprehensive billing expertise and strategic funding programs. Our unique approach ensures our partners achieve unmatched success while transforming healthcare delivery across the U.S. Visit: www.dmeauthority.com
About Therma Bright Inc.
Therma Bright develops and partners on cutting-edge diagnostic and medical device technologies that address key healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as future sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/237912
FAQ**
What specific distribution strategies does DME Authority plan to implement to maximize the sales potential of Venowave VW5 within its partner network, as mentioned in the Therma Bright Inc. THRM:CC announcement?
How does Therma Bright Inc. THRM:CC intend to leverage the positive results from pilot trials to enhance the credibility and market acceptance of Venowave VW5 in the competitive vascular compression therapy market?
Considering the projected $6.72 billion market by 203what unique competitive advantages does Venowave VW5 offer that could position Therma Bright Inc. THRM:CC ahead of other players in the vascular compression therapy landscape?
What specific metrics or key performance indicators will Therma Bright Inc. THRM:CC and DME Authority track to assess the effectiveness of their distribution partnership and the market uptake of Venowave VW5?
**MWN-AI FAQ is based on asking OpenAI questions about Therma Bright Inc. (TSXVC: THRM:CC).
NASDAQ: THRM:CC
THRM:CC Trading
-2.78% G/L:
$0.175 Last:
379,113 Volume:
$0.175 Open:
